6-K 1 f6k_112122.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 9, 2022

001-36686

(Commission file number)

Forward Pharma A/S

(Translation of registrant’s name into English)

Østergade 24A, 1st Floor

1100 Copenhagen K, Denmark

(Address of principal executive office)

________________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐  No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐  No ☒

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐  No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Item 1.

Other Items

On November 21, 2022, Forward Pharma A/S (the “Company”) made available on its website Amended and Restated Articles of Association, dated November 9, 2022, which were filed with the Danish Business Authority on November 14, 2022. The Amended and Restated Articles of Association reflect changes due to the exercise of warrants.

The Company has filed as an exhibit to this Form 6-K the Amended and Restated Articles of Association, dated November 9, 2022.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 21, 2022		Forward Pharma A/S

	By:	/s/ Claus Bo Svendsen
		Name:  Claus Bo Svendsen
		Title:    Chief Executive Officer

EXHIBIT INDEX

99.1	Amended and Restated Articles of Association, dated November 9, 2022.

SEC Form 6-K filed by Forward Pharma A/S